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Background: Cystic fibrosis (CF) remains a lethal condition where a palliative approach is often taken at the end of life. We wanted to
evaluate how lung transplantation impacts end of life care in adult CF patients.
Methods: Data were abstracted using a standardized data collection instrument from all outpatient and inpatient records of adult CF patients
with an FEV1≤30% or prior lung transplantation followed at our Center. Comparisons were made between those who were listed/received
lung transplant and those who were not listed.
Results: A total of 41 patients met the entry criteria. Of these, 63% (n=26) were referred for lung transplant evaluation and 39% (n=16) had
undergone lung transplantation. Of these 41, 59% (n=24) are deceased. The majority of deceased patients expired in an acute care hospital
(63%, n=15). There was no difference in site of death between the two groups (hospital versus home). However, listed/transplanted patients
were more likely to die in an intensive care unit setting compared to patients not listed/transplanted ( p=.013).
Conclusions:Most of our CF patients' deaths occurred in an acute care hospital. Lung transplant significantly alters site of death and shifts it
from medical floors to the intensive care unit.
© 2007 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Lung transplantation; End of life; Palliative care1. Introduction
The median age of survival for patients with cystic
fibrosis (CF) has improved — currently 36.5 years in the
United States [1] — yet CF remains a progressive disease
with an early mortality. Most patients will die as a result of
their airways disease, either from respiratory failure or from a
complication of lung transplantation [1]. CF patients with
severe lung disease who suffer respiratory failure have poor☆ Portions of this work were presented at the North American Cystic
Fibrosis Conference (NACFC) in October 2005.
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doi:10.1016/j.jcf.2007.03.002outcomes with mechanical ventilation with little potential for
short- or long-term survival [2]. Thus, it has been recom-
mended that a palliative approach be considered for CF
patients with advanced lung disease [3].
Despite the high mortality rate in CF, there is a paucity of
literature on end of life care for CF patients. Both theoretical
and qualitative aspects of end of life care for CF patients
have been investigated but with little empirical substantia-
tion [4,5]. Survey research in Canada suggests CF patients
tend to die in an acute care hospital but not receiving critical
care therapies [6]. One center reported that their patients
were likely to die in an acute care hospital receiving both
palliative and curative therapies (e.g. antibiotics) with a Do-
Not-Resuscitate (DNR) status established just prior to death
[7]. This report was a retrospective analysis of their center
data in a period of time preceding the advent of lung trans-
plantation, a procedure that offers prolongation of life in
select patients with end-stage lung disease. A more recent
review has described more favorable outcomes in 42 CFed by Elsevier B.V. All rights reserved.
Table 1
Reasons for not receiving lung transplantation in advanced cystic fibrosis











Listed but not transplanted n=4
Awaiting transplant n=2
Died on waiting list n=2
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ventilation [8]. However, 19 (45%) of the patients died in the
ICU and of the 23 survivors, 3 patients died within 6 months
and 17 patients underwent lung transplantation, half of them
while on the ventilator. Only 3 patients were alive at one year
without lung transplantation.
Lung transplantation is a final therapeutic option for CF
patients with the promise of prolonged life and improved
quality of life [9–11]. However, lung transplantation carries
substantial physical, emotional, and economic costs, and is
not appropriate for some CF patients [12,13]. Prolonged
waiting time and organ scarcity means many patients will not
survive to receive a transplant [14]. Even for those who
undergo lung transplantation, approximately 10% will not
survive the first year and the 5-year survival is 50%
[10,11,13]. Thus, end of life care will remain an important
subject for all CF patients with severe lung disease including
those with lung transplantation. There are no published
investigations of the impact that lung transplant has on end of
life care for CF patients. We sought to assess the patterns of
end of life care for CF patients with advanced lung disease
and to determine the effect that lung transplantation has on
the site of death in these patients.Fig. 1. Stepwise lung transplantation traj2. Materials and methods
2.1. Study design
This study was approved by our local Institutional
Review Board for Human Subjects. We performed a
retrospective chart review of both inpatient and outpatient
records on all patients seen in our Adult Cystic Fibrosis
Program between the years 1995 and 2005. A standardized
data collection instrument was created to collect information
on patients with advanced lung disease, defined as a
documented FEV1b30% predicted or prior lung transplan-
tation. The data collected included demographics (age, sex,
insurance status, education level, marital status), health
status (albumin, body mass index, sputum microbiology,
number of hospitalizations in the last 12 months), and
information related to lung transplantation (e.g. was the
patient referred/listed/transplanted, reasons for not being
referred or listed). For subjects who had died, information on
care at the end of life was collected. Variables of interest
included: site of death (home versus hospital), intensive care
unit (ICU) therapies, documentation of DNR status prefer-
ence, as well as its timing relative to death, therapies at the
time of death (antibiotics, chest physiotherapy, nutritional
supplements, oxygen, non-invasive positive pressure venti-
lation, pain medications, anxiolytics, pharmacologic treat-
ment of dyspnea), and diagnostic testing near the time of
death as defined by 24 h prior to death.
2.2. Statistical analysis
For analytic purposes several subgroups were created.
Groups included: deceased patients, surviving patients,
listed/lung transplanted, and not listed/transplanted. Descrip-
tive statistics were computed for variables of interest.
Comparisons between groups were made using t-tests, chi-
square testing, and Fisher's exact test as appropriate. SPSS®
Statistical Software version 14.0 was used for all analysis.ectory in advanced cystic fibrosis.
Table 3
Therapies at the end of life in cystic fibrosis (n=20)
Therapy % (n)
Conventional CF therapies
• Chest physiotherapy 65 (13)
• Antibiotics 70 (14)
• Vitamins 60 (12)
• Diagnostic testing 80 (16)
• Oxygen therapy 95 (19)
Palliative therapies
• Opiates for pain 95 (19)
• Opiates for dyspnea 75 (15)
• Anxiolytics 60 (12)
• Non-invasive positive pressure ventilation 45 (9)
• ʻDNRʼ order within 24 h of death 70 (14)
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nificance was defined as .05.
3. Results
Forty-one patients met the inclusion criteria. Fifteen
patients (37%) had not been referred for possible transplant
evaluation. They were not referred for a variety of reasons
listed in Table 1. There was documentation of a discussion
regarding transplantation for most of these 15 patients
(n=11; 73%); one had moved and no documentation was
found for 3 patients. The most common reasons for not
referring patients for transplant evaluation were because the
patient was thought to be a poor candidate for transplant
(n=5) or because the patient had declined a referral (n=4).
Of the 26 patients (63%) who were referred for lung trans-
plant evaluation, 6 of them (23%) were not listed for
transplant (Table 1).
When we compared the characteristics of patients who
were either not referred or not listed for transplant (n=21) to
those who were ultimately listed or received a transplant
(n=20), we found no differences in sex, age or marital status.
There was a tendency for patients with more education or
with private insurance to be listed for transplant. Thirty-four
percent of patients listed/transplanted had at least some
college compared to 18% of those not eligible for transplant
( p=0.11). Sixty percent of listed/transplanted patients had
private insurance compared to 29% of patients not listed for
transplant ( p=0.06). Of the eight patients ultimately deemed
to be poor candidates for lung transplantation, most had
inadequate social support systems (n=7 of 8) and two of
these had concomitant substance addiction. Poor nutrition/
debility prevented one patient from being listed.
The transplant trajectory for our patients is shown in Fig. 1.
As can be seen, though most of the patients referred for
transplant evaluation were listed for the procedure (77% of
referred patients), only about half (49%) of all CF patients with
advanced lung disease ultimately were listed for transplant.
Next we investigated end of life care among the patients
who have died. This represented 24 of the 41 individuals in
our study (59%) including 15 patients who were not listed
for transplant (71% of those not listed) and 9 patients who
were listed/received lung transplant (45%). In this latter
group, 2 patients died awaiting transplant, and 7 died at some
time following transplantation. The median time from trans-
plant to death was 6 years (range 0 to 9 years). The medianTable 2
Impact of lung transplantation on site of death among hospitalized cystic
fibrosis patients








ICU 5 3 8
Total 5 11 16 .013survival of all of our CF patients following lung transplan-
tation is 5 years.
Most patients who died did so in a hospital setting (n=16
of 24 patients; 67%); 8 patients were known to have died at
home (33%). Eight patients died on a medicine ward and
8 patients died in an intensive care unit (ICU). Of those who
died in the hospital, the patients in the non-transplant group
generally died on a medicine ward, while those in the listed/
transplanted group died in an ICU (Table 2, p=0.013).
Information regarding therapies at the end of life was
available for 20 of 24 deceased patients. Generally, deceased
CF patients continued receiving conventional CF therapies
such as chest physiotherapy, antibiotics, vitamins, and
diagnostic testing within 24 h of the time of death. The
addition of palliative therapies such as opiates for treatment
of pain and dyspnea and anxiolytics was common at the end
of life (Table 3). Most patients hospitalized at our institution
had a DNR order in the medical record within 24 h of the
time of death.
Finally, we reviewed the medical records specifically for
documentation of end of life preferences in advance of a
terminal hospitalization. FewCF patients livingwith advanced
lung disease had documented end of life discussions (n=1),
whereas most deceased CF patients had a documented end of
life discussion in the medical record that was recorded during
the terminal hospitalization (n=14, 70%).
4. Discussion
Our center has not had a pre-scripted approach to end of
life care, so this retrospective evaluation of our experience
has been enlightening. In many respects, our experience is
much like that reported by Robinson et al. [7]. That is, our
patients who have died often did so in the hospital, receiving
both curative and palliative therapies to the end, and without
the use of the ICU. The exceptions to this rule, however, are
those patients who have a connection with lung transplan-
tation, either by being listed for or having undergone the
procedure. These patients were more likely to have died in
the ICU having received invasive ventilatory support. Thus,
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approach to the end of life in our CF patients with advanced
lung disease.
Prior to the advent of lung transplantation there were
limited options for CF patients with advanced lung disease in
terms of prolongation of life. The experience with intubation
and mechanical ventilation was generally poor [2]. Many CF
clinicians felt that mechanical ventilatory support was non-
beneficial for patients with end-stage lung disease and
advocated for conventional CF therapies and a palliative
approach [2,3,7]. Once lung transplant became available it
was quickly demonstrated that some patients who suffered
respiratory failure necessitating mechanical ventilation could
undergo lung transplant successfully [8,15]. This has led to
greater use of mechanical ventilation in CF patients as doc-
umented in the experience of Sood et al. [8]. However,
what is clear from their data is that in the absence of trans-
plantation, their experience with CF patients on mechanical
ventilation is similar to what had previously been reported
— CF patients with advanced lung disease do poorly with
mechanical ventilation.
In our series of 41 patients, 23 (56%) did not experience
the opportunity for lung transplantation. This includes 15
patients who were not referred for evaluation, 6 patients who
were evaluated but not listed for transplant, and 2 patients
who died on the waiting list. These findings preclude the
recent change in lung allocation from time-based to priority-
based [16]. It is possible that the three patients who died
awaiting lung transplant would have benefited from this
change but is unlikely to have altered how transplanted
versus non-transplanted patients ultimately died.
It remains to be seen whether the new organ allocation
system will affect the number of CF patients who die
awaiting transplantation. However, many CF patients with
advanced lung disease will remain ineligible for lung
transplant. In the US, 21.4% of adults and 2.6% of children
with CF are living with advanced lung disease (defined by
the CFF as FEV1b40% predicted) which equates to over
2500 individuals [1]. If our CF patients are assumed to be
representative of the general CF population, then for the
majority of CF patients with advanced lung disease,
regardless of transplant status, it would seem appropriate
that there should be a plan for the end of life.
The documentation of an end of life plan, including a
DNR status, was not common in the medical records of our
patients unless they died while hospitalized (in which case
DRN orders were in the medical record). An end of life
discussion is inferred because the patients who did not un-
dergo transplant evaluation — a discussion that was
typically documented — did not die in the ICU setting but
instead died receiving palliative therapies, such as opiates for
pain and dyspnea (Table 3). Furthermore, these patients were
all cared for by a single CF provider (PF) and stable CF team
who habitually address end of life care when patients
develop advanced lung disease and often do so in the context
of lung transplant discussion. The use of curative therapiesmight be viewed as inconsistent with a palliative approach to
the end of life. However, as discussed by Robinson et al. [7],
there are several reasons why such therapies might be
administered to the end, the most important being that some
curative therapies may also be considered palliative. Medi-
cations or therapies to clear airway secretions and antibiotics
to reduce the burden of infection may lead to reduction in
suffering in the final days of life.
So, what conclusion should be drawn regarding the
impact that lung transplantation has on care at the end of
life and specifically on the use of the ICU and mechanical
ventilation? It would be difficult to criticize the use of
mechanical ventilation in patients who are waiting for trans-
plant, assuming they have a legitimate opportunity to receive
a transplant. These patients have already expressed a desire
to pursue aggressive therapies in the hope of life prolonga-
tion. The same could be argued for those patients who are
suffering complications such as infection or acute rejection
in the period immediately following transplantation. How-
ever, what is the best approach for the patients post-
transplantation who are approaching the outer limits of
transplant viability? Median survival following lung trans-
plant is 5 years and the period of transplant decline is often
marked by recurrent and progressive lung disease due to
obliterative bronchiolitis [11]. It is reasonable to hypothesize
that patients opting for aggressive therapies such as lung
transplant may continue to desire aggressive therapy even
when it may be non-beneficial. However, it is equally rea-
sonable to hypothesize that providers offer more aggressive
care without considering whether a lung transplant patient
has attained the outer limits of survivability.
While our findings may have important implications for
end of life care in CF there are limitations that must be
considered. First, this is a retrospective evaluation using data
obtained from the medical record. The documentation may
not accurately represent the conversations between the
clinician and patient regarding transplant and end of life
preferences. Second, due to incomplete documentation in the
medical record and to the fact that some of our patients had
moved near the end of life, there are missing data on some
aspects of end of life care. We were able to obtain location of
death for all deceased patients but were unable to find detail
about therapies at the end of life for some (n=4). Third, these
patients received their care from a single, university-based,
adult CF program and may not represent the end of life
practices at other centers. It is tempting to suggest that since
there were similarities between our findings and those of
another center [7], that this is the common experience at CF
centers, but this assumption should not be made. Finally, the
numbers of patients in this series are relatively few posing a
risk of statistical instability and more could certainly be
learned from a larger, prospective, multi-center survey.
Nonetheless, even with so few patients, the data met statis-
tical significance, consistent with a striking difference.
In conclusion, our findings of care of CF patients with
advanced lung disease raise important questions regarding
395D. Ford, P.A. Flume / Journal of Cystic Fibrosis 6 (2007) 391–395the end of life. Again, if we assume our findings to be
representative of other CF centers, half of CF patients with
advanced lung disease will not receive a lung transplant, and
half of those who do will die in less than 5 years, suggesting
that about 75% of CF patients with advanced lung disease
may be in the last 5 years of their life, even in an era of lung
transplantation. Thus, we cannot escape the reality of the
approaching end of life in our patients and this very im-
portant issue must be addressed. Future investigations should
seek to describe patterns of end of life care at other CF
centers and incorporate lung transplant into the analysis.
Additionally, while these data describe where CF patients die
and what therapies they receive, the overall quality of the
dying experience has not been determined and remains an
important unanswered question.
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